178 related articles for article (PubMed ID: 18029374)
1. Think of oxalate when using ascorbate supplementation to optimize iron therapy in dialysis patients.
Canavese C; Marangella M; Stratta P
Nephrol Dial Transplant; 2008 Apr; 23(4):1463-4; author reply 1464. PubMed ID: 18029374
[No Abstract] [Full Text] [Related]
2. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
3. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
Sirover WD; Siddiqui AA; Benz RL
Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
[TBL] [Abstract][Full Text] [Related]
4. [Iron poisoning as a risk in the treatment of nephrogenic anemia].
Hansen BL; Pedersen FB
Ugeskr Laeger; 1985 Aug; 147(35):2747-9. PubMed ID: 4071711
[No Abstract] [Full Text] [Related]
5. [Quinbolone in the therapy of anemia in uremic patients during periodic hemodialytic treatment].
Amato M; Bigioli F; Beconi D; Martinelli F; Lapini V; Salvadori M
Clin Ter; 1980 Jul; 94(1):57-65. PubMed ID: 7438723
[No Abstract] [Full Text] [Related]
6. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients.
Arduini A; Bonomini M; Clutterbuck EJ; Laffan MA; Pusey CD
Nephrol Dial Transplant; 2006 Sep; 21(9):2671-2. PubMed ID: 16611680
[No Abstract] [Full Text] [Related]
7. Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient.
D'Costa MR; Winkler NS; Milliner DS; Norby SM; Hickson LJ; Lieske JC
Am J Kidney Dis; 2019 Sep; 74(3):417-420. PubMed ID: 30910370
[TBL] [Abstract][Full Text] [Related]
8. [Hematologic changes in chronic uremia].
Schnurr E
Dtsch Med Wochenschr; 1979 Nov; 104(47):1678-82. PubMed ID: 510197
[No Abstract] [Full Text] [Related]
9. A Case of Oxalate Nephropathy: When a Single Cause Is Not Crystal Clear.
Marques S; Santos S; Fremin K; Fogo AB
Am J Kidney Dis; 2017 Nov; 70(5):722-724. PubMed ID: 28739328
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. The effect of histidine supplementation on the anemia of uremia.
Blumenkrantz MJ; Shapiro DJ; Swendseid ME; Kopple JD
Proc Clin Dial Transplant Forum; 1974; (4):152-5. PubMed ID: 4468412
[No Abstract] [Full Text] [Related]
12. The clinical significance of assessment of serum calcium oxalate saturation in the hyperoxaluria syndromes.
Marangella M; Vitale C; Petrarulo M; Linari F
Nephrol Dial Transplant; 1995; 10 Suppl 8():11-3. PubMed ID: 8592617
[TBL] [Abstract][Full Text] [Related]
13. [19-norandrostenolone undecylate in the treatment of anemia in patients treated with periodic hemodialysis].
Docci D; Feliciangeli G; Mosconi G; Vangelista A; Stefoni S
G Clin Med; 1981 Aug; 62(8):567-75. PubMed ID: 7308639
[No Abstract] [Full Text] [Related]
14. [Testosterone in the therapy of anemia in the uremic patient treated by periodic hemodialysis].
Brancaccio D; Pincella G; Graziani G; Redaelli B
Minerva Nefrol; 1972; 19(4):269-73. PubMed ID: 4681104
[No Abstract] [Full Text] [Related]
15. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.
Hedenus M; Näsman P; Liwing J
J Clin Pharm Ther; 2008 Aug; 33(4):365-74. PubMed ID: 18613854
[TBL] [Abstract][Full Text] [Related]
17. Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Nephrol Dial Transplant; 1995 Dec; 10(12):2321-4. PubMed ID: 8808233
[No Abstract] [Full Text] [Related]
18. Minimizing anemia in the chronic hemodialysis patient.
Norris SH; Kurtzman NA
Int J Artif Organs; 1986 Jul; 9(4):199-206. PubMed ID: 3781644
[No Abstract] [Full Text] [Related]
19. Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane (BK-F).
Yamada S; Kataoka H; Kobayashi H; Ono T; Minakuchi J; Kawano Y
Contrib Nephrol; 1999; 125():159-72. PubMed ID: 9895438
[No Abstract] [Full Text] [Related]
20. [New pathogenetic views on renal anemia].
Lamperi S
Minerva Nefrol; 1982; 29(2):61-70. PubMed ID: 6752763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
